Objective: To explore the expression characteristics of C5a receptor (C5aR1), bradykinin receptor B1 (BDKRB1), hypoxia inducible factor-1α (HIF-1α) and G0/G1 switch 2 (G0S2) genes in the Correa development model of intestinal gastric cancer, and to screen the predictors of the progression of gastric precancerous lesions. Methods: The paraffin blocks of chronic non-atrophic gastritis (CNAG), chronic atrophic gastritis (CAG), low-grade intraepithelial neoplasia (LGIN), high-grade intraepithelial neoplasia (HGIN), early gastric cancer (EGC) and early gastric cancer in submucosa were selected. The protein expression levels of C5aR1, BDKRB1, G0S2 and HIF-1α in each tissue were detected by immunohistochemistry. Results: C5aR1 was mainly expressed in cell membrane and cytoplasm, BDKRB1 was mainly expressed in cell membrane, G0S2 and HIF-1α were mainly expressed in cytoplasm and nucleus. The expression levels of C5aR1, BDKRB1 and G0S2 in HGIN and EGC tissues were significantly higher than those in CAG and CNAG tissues(P＜0.001). The expression level of HIF-1α in HGIN and EGC tissues was significantly higher than that in CNAG(P＜0.001), but there was no statistical difference compared with CAG. There was no significant difference in the expression of the four factors between LGIN and other tissues, and there was no significant difference in the expression of CNAG and CAG tissues. Conclusion: The expressions of C5aR1, BDKRB1, G0S2 and HIF-1α increase with the Correa development stage of intestinal type gastric cancer, which may have the value of predicting the progression of gastric precancerous lesions.
LI Yang
,
NIAN Yuanyuan
,
MENG Xianmei
. Predictive value of C5aR1, BDKRB1, G0S2 and HIF-1α in the progression of gastric precancerous lesions*[J]. Journal of Baotou Medical College, 2025
, 41(5)
: 72
-76
.
DOI: 10.16833/j.cnki.jbmc.2025.05.014
[1] Xia C, Dong X, Li H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants[J]. Chin Med J (Engl), 2022, 135(5): 584-590.
[2] Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. an attempt at a histo-clinical classification[J]. Acta Pathol Microbiol Scand, 1965, 64: 31-49.
[3] Chen YC, Fang WL, Wang RF,et al. Clinicopathological variation of lauren classification in gastric cancer[J]. Pathol Oncol Res, 2016, 22(1): 197-202.
[4] Correa P, Piazuelo MB. The gastric precancerous cascade[J]. J Dig Dis, 2012, 13(1): 2-9.
[5] 中华中医药学会脾胃病分会, 中华医学会消化病学分会消化肿瘤协作组, 中华医学会消化内镜学分会早癌协作组, 等. 中国整合胃癌前病变临床管理指南[J]. 胃肠病学, 2021, 26(2): 91-111.
[6] 许青,郭献灵,赵昆.对Correa级联反应的完整确认: 西方低危发病人群胃癌前病变患者胃癌发病率的观察性队列研究[J].循证医学,2016,16(5): 274-275.
[7] Ding P, Xu Y, Li L, et al. Intracellular complement C5a/C5aR1 stabilizes β-catenin to promote colorectal tumorigenesis[J]. Cell Rep, 2022, 39(9): 110851.
[8] Carvalho K, Schartz ND, Balderrama-Gutierrez G, et al. Modulation of C5a-C5aR1 signaling alters the dynamics of AD progression[J]. J Neuroinflammation, 2022, 19(1): 178.
[9] Gomez-Arboledas A, Carvalho K, Balderrama-Gutierrez G, et al. C5aR1 antagonism alters microglial polarization and mitigates disease progression in a mouse model of Alzheimer's disease[J]. Acta Neuropathol Commun, 2022, 10(1): 116.
[10] Nürge B, Schulz AL, Kaemmerer D, et al.Immunohistochemical identification of complement peptide C5a receptor 1 (C5aR1) in non-neoplastic and neoplastic human tissues[J]. PLoS One, 2021, 16(2): e0246939.
[11] Angers M, Drouin R, Bachvarova M, et al. In vivo DNase I-mediated footprinting analysis along the human bradykinin B1 receptor (BDKRB1) gene promoter: evidence for cell-specific regulation[J]. Biochem J, 2005, 389(Pt 1): 37-46.
[12] Li L, Liu X, Wen Y, et al. Identification of prognostic markers of DNA damage and oxidative stress in diagnosing papillary renal cell carcinoma based on high-throughput bioinformatics screening[J].J Oncol, 2023, 2023: 4640563.
[13] Bejrananda T, Saetang J, Sangkhathat S. Molecular subtyping in muscle-invasive bladder cancer on predicting survival and response of treatment[J]. Biomedicines, 2022, 11(1): 69
[14] Zhang Q, Ruan H, Wang X,et al..Ulinastatin attenuated cardiac ischaemia/reperfusion injury by suppressing activation of the tissue kallikrein-kinin system. Br J Pharmacol. 2024; 181(24): 4988-5008.
[15] Basuli D, Parekh RU, White A, et al. Kinin B1 Receptor Mediates Renal Injury and Remodeling in Hypertension[J]. Front Med (Lausanne), 2022, 8: 780834.
[16] Kuang M, Cheng J, Zhang C, et al. A novel signature for stratifying the molecular heterogeneity of the tissue-infiltrating T-cell receptor repertoire reflects gastric cancer prognosis[J]. Sci Rep, 2017, 7(1): 7762.
[17] Heckmann BL, Zhang X, Xie X, et al. The G0/G1 switch gene 2 (G0S2): regulating metabolism and beyond[J]. Biochim Biophys Acta, 2013, 1831(2): 276-281.
[18] Zhao NQ, Li XY, Wang L, et al. Palmitate induces fat accumulation by activating C/EBPbeta-mediated G0S2 expression in HepG2 cells[J]. World J Gastroenterol, 2017, 23(43): 7705-7715.
[19] Welch C, Santra MK, El-Assaad W, et al. Identification of a protein, G0S2, that lacks Bcl-2 homology domains and interacts with and antagonizes Bcl-2[J]. Cancer Res, 2009, 69(17): 6782-6789.
[20] Yim CY, Sekula DJ, Hever-Jardine MP, et al. G0S2 Suppresses Oncogenic Transformation by Repressing a MYC-Regulated Transcriptional Program[J]. Cancer Res, 2016, 76(5): 1204-1213.
[21] Payne KJ, Dovat S. G0S2--a new player in leukemia[J]. Leuk Res, 2014, 38(2): 147-148.
[22] Kitareewan S, Blumen S, Sekula D, et al. G0S2 is an all-trans-retinoic acid target gene[J]. Int J Oncol, 2008, 33(2): 397-404.
[23] Corbet AK, Bikorimana E, Boyd RI, et al. G0S2 promotes antiestrogenic and pro-migratory responses in ER+ and ER- breast cancer cells[J]. Transl Oncol, 2023, 33: 101676.
[24] Rashid M, Zadeh LR, Baradaran B, et al. Up-down regulation of HIF-1α in cancer progression[J]. Gene, 2021, 798: 145796.
